Amid Immunocore’s C-suite bloodletting Glaxo provides solace
Immunocore has recently been beset with multiple senior executive departures, but has managed to press on into phase I with a Glaxo-partnered asset.
Why Immatics could soon become the next listed cell therapy player
Immunocore and Adaptimmune could shortly have a publicly listed rival.
Corporate venture firms – dedicated followers of fashion?
Eagerly pursuing all the latest fads and trends.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.